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Background: Presently, few data exist on the level and duration of anti-protective antigen (PA) IgG in vaccinated
livestock. Various adaptation of enzyme-linked immunosorbent assays (ELISAs) have been developed in studies
to assess immune response following vaccination, albeit mostly in laboratory rodent models. The quantitative
anti-anthrax IgG ELISA in this study describes a method of enumerating the concentration of anti-PA specific IgG
present in sera of immunized goats, with the aid of an affinity-purified caprine polyclonal anti-anthrax PA-83 IgG
standard. This was compared with the anthrax toxin neutralization assay (TNA) which measures a functional subset of
toxin neutralizing anti-PA IgG.
Results: The measured concentrations obtained in the standard curve correlated with the known concentration at
each dilution. Percentage recovery of the standard concentrations ranged from 89 to 98% (lower and upper asymptote
respectively). Mean correlation coefficient (r2) of the standard curve was 0.998. Evaluation of the intra-assay coefficient
of variation showed ranges of 0.23-16.90% and 0.40-12.46% for days 28 and 140 sera samples respectively, following
vaccination. The mean inter-assay coefficient of variation for triplicate samples repeated on 5 different days was 18.53
and 12.17% for days 28 and 140 sera samples respectively. Spearman’s rank correlation of log-transformed IgG
concentrations and TNA titres showed strong positive correlation (rs = 0.942; p = 0.01).
Conclusion: This study provides evidence that an indirect ELISA can be used for the quantification of anti-anthrax PA
IgG in goats with the added advantage of using single dilutions to save time and resources. The use of such related
immunoassays can serve as potential adjuncts to potency tests for Sterne and other vaccine types under development
in ruminant species. This is the first report on the correlation of polyclonal anti-anthrax PA83 antibody with the TNA in
goats.
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GoatsBackground
Bacillus anthracis is a spore-forming bacterium that
causes anthrax primarily in herbivorous animals but also
affecting other mammalia including humans to a lesser
extent [1]. The virulence factors of B. anthracis are
encoded on the pXO1 and pXO2 plasmids. The pXO1
plasmid carries the genes pagA, lef, and cya that encode
the protective antigen (PA), lethal factor (LF), and oedema
factor (EF), respectively [2]. The term “protective antigen”* Correspondence: okeyndumnego@yahoo.com
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article, unless otherwise stated.was derived because of the protein’s ability to elicit a pro-
tective immune response against anthrax [3]. Individually,
none of these proteins are toxic, but PA combines with EF
to form the oedema toxin (ET). Similarly, PA in combin-
ation with LF forms the anthrax lethal toxin (LT) [2,4,5].
The pXO2 plasmid codes for the anti-phagocytic poly-
gamma-D-glutamic acid (PGDA) capsule which protects
the bacteria against phagocytosis, or consumption by de-
fensive cells of the immune system. Various studies have
shown that without its capsule, the bacteria can be phago-
cytized and destroyed [6,7]. Attenuated strains that lack
either of the plasmids have a reduced virulence [1].ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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ated B. anthracis 34 F2 strain which was developed in
1937 by Max Sterne at Onderstepoort in South Africa
[8]. Sterne derived a rough variant of virulent B. anthra-
cis by culturing the organism on serum agar in elevated
CO2 atmosphere. The attenuation of this strain was sub-
sequently shown to be due to loss of the capsule-
encoding pXO2 plasmid [9]. Compared to wild type B.
anthracis strains, the Sterne strain is relatively avirulent
but immunization of animals with the strain is able to
stimulate a protective immune response. The Sterne vac-
cine consist of 1–5 × 106 spores per dose suspended in
glycerine and is administered subcutaneously [10]. Ivins
et al. [11] in his study concluded that the nontoxigenic
Pasteur vaccine lacking the pXO1 plasmid did not pro-
vide protection and that attenuated, live B. anthracis
strains must produce the toxin components to enable
successful immunization. Presently, the Sterne live spore
vaccine is the most widely used strain for immunization
of animals against anthrax.
The efficacy of the Sterne vaccine was originally
assessed by virulent challenge of vaccinated sheep, guinea
pigs, cattle, horses, goats and rabbits. These trials were
not comparable as the vaccine/challenge doses and strains
varied in the different animal species [1]. Furthermore, ad-
verse reactions in goats vaccinated with the Sterne vaccine
was reported by Sterne [12]. Lincoln et al. [13] indicated
that the susceptibility of animal species to anthrax is pro-
portional to their susceptibility to the anthrax toxin. This
focused research on the development and improvement of
serological tests to assess protection provided by anthrax
vaccines. Serological tests before the 1980s lacked sensitiv-
ity and/or specificity [14]. This problem was surmounted
by the purification of the PA component of the anthrax
toxin [15,16] and the application of the enzyme-linked im-
munosorbent assay (ELISA) that was highly sensitive in
detecting anti-anthrax antibodies. ELISAs have been
widely used in the diagnosis of anthrax and the develop-
ment of new anthrax vaccines [17,18]. However, little data
exists on the prevalence, the level of- and the duration of
anti-anthrax antibodies in vaccinated livestock. Various
versions and adaptations of ELISAs have been developed
in several studies to assess the immune response following
vaccination, though mostly in laboratory rodent models.
Evaluating immune response in vaccinates by a titre-based
ELISA method has been used previously in vaccine
potency and immunogenicity studies in the veterinary
field [19-21]. The quantitative anti-anthrax IgG ELISA in
this study describes a method of enumerating the concen-
tration of anti-PA specific IgG present in sera of immu-
nized goats, with the aid of an affinity-purified caprine
polyclonal anti-anthrax PA83 IgG standard. This method
will be compared with the anthrax toxin neutralization
assay (TNA).The TNA is a technique developed to measure the
ability of antibodies in sera of immunized animals to
neutralize the PA and its contribution to LT cytotoxicity
for certain sensitive cell lines [22-24]. This technique is
species independent and has been standardized for use
with multiple species [25-27]. Therefore this study in-
volved the adaptation and optimization of the quantita-
tive anti-anthrax IgG ELISA in goats and its comparison
with the standard anthrax TNA. It attempts to address
the feasibility of the use of a quantitative anti-PA anti-
body ELISA in evaluating the immunoglobulin kinetics
in an immunized caprine model.
Results
Evaluation of characteristics of reference standard
4-parameter curve
Data from 22 reference standard curves made up of 10,
two-fold serial dilutions from 5–0.0098 μg/ml were
calculated to be A = 0.0270 ± 0.0132; B = 1.151 ± 0.0467;
C = 0.4268 ± 0.1576 and D = 3.473 ± 0.1154 (±SD). A
good %Re was recorded for the nominal concentrations
(Figure 1) with the only exception being at the lower
asymptote (89%) for the 0.0098 μg/ml concentration
though well within the established acceptable range of
80% for lower limit of quantitation [28]. The mean cor-
relation coefficient (R2) of the standard curves was
0.9998 (Figure 2) with ranges between 0.9998 and 1.0000.
Precision of assay
Evaluation of the intra-assay coefficient of variation
showed ranges from 0.23 - 16.9% and 0.40 - 12.46% for
day 28 and 140 sera respectively. Average inter-assay CV
was 18.53% for day 28 sera and 12.17% for day 140 sera
collection (Table 1). Slightly higher CV values were ob-
served with the day 28 sera compared to sera collected
140 days after vaccination.
Correlation between quantitative ELISA and toxin
neutralization assay
We investigated the ability of the collected caprine sera
to protect susceptible mouse macrophages from the dele-
terious effects of anthrax lethal toxin using the TNA. The
toxin neutralizing titres of sera from individual animals
at specific time-points were compared with the corre-
sponding IgG concentration using the Spearman’s rank
correlation test. The scatter plot (Figure 3) indicates a
similar correlation between the log TNA and IgG values
at days 28 and 140 post-vaccination respectively. Spear-
man’s rank correlation of the log-transformed IgG con-
centrations and TNA titres showed strong positive
correlation (rs = 0.942; p = 0.01). TNA values for the day
0 sera were negligible, being below the starting dilution
of 50 for the assay (not shown).






















Figure 1 Percentage recovery (%Re) plots for known concentrations of the reference anti-PA IgG standard. %Re indicates percentage
recovery for known IgG concentrations of the standard that were tested in the ELISA using a 4-parametre logistic curve model. [%Re = 100(BC/
NC), where BC and NC represent the back-calculated and nominal (known) concentrations respectively].
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Very little data is available on the kinetics of anthrax anti-
bodies in vaccinated livestock and the duration of immun-
ity. The use of immunoassays could serve as adjuncts to
potency tests for the Sterne and other vaccine types under
development. In this study we have modified and adapted
an ELISA [29] for the quantitation of anti-PA immuno-
globulins in goats vaccinated with the Sterne live spore
vaccine. This study investigated the feasibility and charac-
teristics of an IgG-quantitative indirect-ELISA using a
standard curve. This approach has been used in the field



















Figure 2 Anti-PA IgG 4-parameter logistic curve model derived for a
derived from a reference standard consisting of affinity-purified caprine po
from 5–0.0098 μg/ml.[30,31]. Correlation between ELISA-measured IgG levels
and TNA derived neutralization titres have been shown
previously in various laboratory species [24,32] but not in
a ruminant species. Therefore the ELISA was also com-
pared to the TNA.
PA is the most essential component of live, inactivated or
protein-based anthrax vaccines [33] and strains of B.
anthracis without the toxin producing plasmid, pXO1, have
failed to confer protective immunity to animals with excep-
tion to mice [33,34]. More so, numerous studies have
shown PA to be able to induce a protective response in ex-
perimental models of infection [35]. Thus, evaluation ofntration (ug/ml)
0.1 1 10
quantitative indirect ELISA using the Gen 5 software. Data were
lyclonal anti-anthrax PA83 IgG fraction with dilutions
Table 1 Mean IgG concentrations for caprine sera
collected on days 0, 28 and 140 days respectively
Day 0 Day 28 Day 140
Animal IgG μg/mL (CV) IgG μg/mL (CV) IgG μg/mL (CV)
#8172 3.2534 (52) 221.8 (16.8) 56.1 (14.9)
#8173 1.1405 (11.5) 719.6 (16.2) 166.2 (15.1)
#8174 0 546.8 (16.3) 102.7 (11.3)
#8175 2.3788 (65.5) 585.9 (17.1) 59.8 (9.9)
#8176 0.8115 (83.9) 584.2 (19.0) 106.3 (11.4)
#8178 1.7455 (14) 464.4 (18.1) 24.7 (13.1)
#8179 1.5884 (64.8) 268.3 (20.1) 55.9 (12.4)
#8180 0 227.2 (16.6) 28.0 (14.5)
#8181 0.115 482.8 (22.3) 41.8 (10.7)
#8182 0 719.0 (22.8) 92.4 (8.44)
Five assays were done in triplicates for each serum sample.
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vaccination is an important step in the evaluation of vac-
cine efficacy due to the essential role played by PA in an-
thrax pathogenesis. Anti-PA antibodies have also been
shown to suppress germination of spores and to enhance
phagocytosis of spores by macrophages and thus preventing
the establishment of infection [36,37]. Seroconversion to
PA specific antibodies following vaccination could be an in-
dication of the immune status in vaccinated herbivores, as
already indicated in laboratory animals [29,36].
Our study evaluated the standard curve on each ELISA
plate and found a high repeatability with an average R2 of
















Figure 3 Scatter plots of log TNA titres by log ELISA μg/ml from sera
quantitative indirect ELISA (in triplicates) and once with the TNA (dup
with the Sterne vaccine. Spearman’s rank correlation of the log-transform
(rs = 0.942; p = 0.01).essential in the development and assessment of quantita-
tive assay characteristics such as accuracy and precision
[38]. The key factor is the level of agreement of known
standard calibrator concentrations with back-fitted con-
centrations with the latter read of the fitted standard curve
as if they were unknown samples [39,40]. The drifting of
the %Re from the ideal 100% can be attributed to stronger
effects of nonspecific binding at the lower asymptote as
antibody concentration reduces dramatically. The same ef-
fect is seen at the upper asymptote possibly due to the
near infinite antibody concentration (maximum response)
though not as pronounced as seen in the lower asymptote.
It can also be posited that the upper and lower limits of
detection of antibodies of this assay are very close to the
respective asymptotes of the standard curve (5 μg/ml and
0.0098 μg/ml respectively). Although %Re of the standard
at both asymptotes is not optimal, this effect can be mini-
mized by the limiting of the calibration to concentrations
within the ideal 100% recovery level. Crucially, the assess-
ment of the suitability of a standard curve for any
immunoassay should be done early in the assay develop-
ment, as a sound calibration curve is central to the devel-
opment of sound assay characteristics [38]. This is also
very important in the further development of the assay
since the quantification of antibodies in test sera is derived
from the standard curve [31,41]. Moreover, the inclusion
of a serially diluted standard reference on every ELISA
plate serves as a normalization and/or internal control for
the individual assays.
The OD405 values of the assay blank wells also fell
within the acceptable level for an early stage ELISATNA Titre
2.2 2.4 2.6 2.8 3.0
of ten goats analysed over five different days with the
licates) on 28 (circles) and 140 (triangles) days after vaccination
ed IgG concentrations and TNA titres showed a positive correlation,
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stead of the conventional foetal calf serum as previously
described [42] improved the specificity of the ELISA (low
background noise). Non-specific binding or low back-
ground noise in an ELISA system has been attributed to
the use of sera as a blocking agent in ELISA systems [42].
This phenomenon was reduced with the use of skimmed
milk powder as the blocking agent of choice.
With the IgG quantitiative ELISA in goats more sera
samples can be assessed on each ELISA plate when com-
pared to the conventional titre-based ELISA where end-
point titrations for each serum sample are performed in
rows on the plates. Good reproducibility of the data was
obtained over five different assays with the CV within
acceptable limits. The CV between different runs (per-
formed on different days) was much lower for sera col-
lected on day 140 compared to samples collected on day
28. This could be due to the presence of more robust
antibodies with higher antigenic affinities.
Assessment of LT neutralizing antibodies by the TNA in
various species has been shown to correlate with survival in
various laboratory animal species [43-45]. These studies
evaluated anthrax PA-based vaccines in laboratory rodents
like guinea pigs, rabbits and mice and found correlation be-
tween toxin neutralizing antibodies and protection [43-45].
This study is the first to quantify anti-PA immunoglobins
in goats using the live Sterne spore vaccine in a host animal
species. It is not known if a correlation between toxin neu-
tralizing antibodies and protection will be observed with a
virulent B. anthracis challenge of the vaccinated goats. Cru-
cially, we have observed a significant positive correlation
between ELISA-derived IgG concentrations and TNA titres
in goats. This is an important step in further studies explor-
ing the correlates of protection against virulent spore chal-
lenge in goats and evaluation of test vaccines. More so, it
will elucidate more on the possible role of anti-PA anti-
bodies in goats, as little is known in this regard.
Conclusion
In summary, though not exhaustive in its approach, this
study indicates that a reliable IgG quantitative ELISA can
be useful for vaccine studies in goats. The assay has the ad-
vantage of a reference standard in every plate which gives a
measure of good internal control, in addition to the positive
and negative controls. The feasibility of a full, long term
validation of the assay seems favourable and should serve




Purified recombinant antigen (rPA83) [29] with concen-
tration of 1450 μg/ml in bicarbonate buffer (0.05 M,
pH 9.5) and stored at −20°C was obtained from Dr.Wolfgang Beyer, Institute of Environmental and Animal
Hygiene, University of Hohenheim, Stuttgart.
Immunization
Ten naïve, age-matched Boer goats were housed at the
experimental animal facility of Onderstepoort Biological
Products (OBP), South Africa and were allowed an
acclimatization period of 14 days. The goats were vacci-
nated subcutaneously on day 0 with 1 ml of the com-
mercial Bacillus anthracis Sterne 34 F2 vaccine (1 × 106
spores/ml) according to the manufacturers’ instruction
(OBP) and monitored throughout the duration of the
trial. Blood was collected on days 0, 28 and 140 respect-
ively. The harvested sera were aliquoted into 1 ml cryo-
vials and stored at −20°C till use. Serum from a goat
revaccinated one year after the first immunization served
as the positive control in the ELISA. The animal re-
search was approved by the animal ethics committee
(AEC) of the University of Pretoria, South Africa (proto-
col approval number V41-10) and the Department of
Agriculture, Forestry and Fisheries, South Africa under
the animals disease act (act 36 Section 20, 1984).
Quantitative indirect anti-PA IgG ELISA
An antibody reference standard that consisted of
affinity-purified caprine polyclonal anti-anthrax PA83
IgG fraction (10 mg/ml) was obtained from Innate Ther-
apeutics (Auckland) and stored at −20°C until used. This
indirect ELISA measured anti-PA83 specific IgG in 96-
well microtitre plates (Maxisorp Nunc-immuno plate,
Germany) coated with rPA83 as the capture antigen.
Each plate contained one duplicate negative control
(from unvaccinated goat), three duplicates positive con-
trol at high, medium and low concentrations, four
blanks and 20 test sera in triplicates at a 1:400 dilution.
The reference standard was titrated in duplicate in a
2-fold dilution series.
Individual wells of the plates were coated with 100 μl of
rPA diluted to 5 μg/ml in bicarbonate buffer [46]. After 24
hours incubation at 4°C, the plates were washed twice
with PBS containing 0.05% Tween 20 (Merck, Pretoria,
South Africa) (PBST) using a Biorad PW 40 washer
(Marnes-La-Coquette, France). Plates were blocked with
200 μl of PBST containing 10% skimmed milk powder
(Oxoid, Hampshire, England) (PBSTM) and incubated for
1 hour at room temperature. The plates were washed as
before and 100 μl of the test sera as well as the reference
standard (5–0.0098 μg/ml) were diluted in PBSTM and
added to the respective wells. Blank wells received only
100 μl of PBSTM. The plates were then incubated for 30
minutes at room temperature on a rotatory plate shaker
(200 rpm) (Titretek® Flow Labs, Irvine, UK). After five
washes, 100 μl of horseradish peroxidase-conjugated
rabbit anti-goat IgG (Invitrogen, Camarillo, CA, USA)
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incubated for 30 minutes as before. After the incubation,
the plates were washed five times before adding 100 μl of
the enzyme substrate 2,2-Azino-bis(3-ethylbenzthiazoline-
6-sulfonic acid) diammonium salt (Sigma, Steinheim,
Germany) to each well. Plates were incubated for 40 mi-
nutes in the dark. Absorbance was measured at 405 nm
using a Biotek power wave XS 2 reader (Winooski, USA).
Plates were blanked with the wells containing PBSTM
only. The anti-PA83 IgG concentration of the sera were
calculated from the corresponding reference standard
curve on the respective ELISA plates using the 4-
parameter logistic regression equation in the Gen5 data
analysis software (Biotek Instruments, USA).
Anthrax toxin neutralization assay (TNA)
The anthrax TNA was performed using the mouse
macrophage cell line J774A.1 (European collection of
cell cultures, ECACC) as previously described [25] with
slight modifications. 96-well flat-bottomed tissue culture
plates (Greiner Bio One, Germany) containing 8 × 104
macrophages/well in DMEM (Life Technologies, USA)
and 10% FCS (Life Technologies, USA) were incubated
overnight at 37°C and 5% CO2. Goat sera were doubly
diluted (1:50 to 1:6400) in culture medium containing
PA and LF (List Biological Laboratories Inc., Campbell,
CA) at concentration of 500 ng/ml and 400 ng/ml (lethal
toxin, LT) respectively. The sera/LT mixture was incu-
bated for one hour at 37°C and 5% CO2 before adding to
overnight cultured cells (after discarding medium) and
incubated for three hours. Each serum sample was tested
in duplicate. Following incubation, 25 μl of 5 mg/ml
MTT (3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide; Life Technologies, USA) was added to
each well and incubated in the dark at 37°C and 5%
CO2. After two hours incubation, the cells were lysed
with prewarmed (37°C) acidified isopropanol (90% iso-
propanol, 0.5% SDS w/v, 25 mM HCl, pH 4.7) by vigor-
ously pipetting up and down to solubilize the formazan
dye. The plates were rested for five minutes and the ab-
sorbance readings taken at 540 nm with a Biotek power
wave XS2 reader. Each assay included a single dilution
series of positive control serum from a goat hyper im-
munized with the Sterne live spore vaccine. Three wells
in each assay receiving LT served as blanks, another trip-
licate of wells (with cells) received only LT as toxin con-
trol while only culture media was placed in two wells
(medium control). The neutralization titre of each test
serum was calculated by: NT50 = (sample – toxin con-
trol)/(medium control – toxin control) × 100 and
expressed as the reciprocal of the highest serum dilution
neutralizing 50% of the LT cytotoxicity. NT50 data were
obtained using the Gen5 data analysis software (Biotek
Instruments, USA).Statistical analysis
For determination of assay precision, serum samples
were tested in triplicates on five different days. Mean ab-
sorbance values, standard deviation and coefficient of
variation (CV) for each duplicate dilution of test sam-
ples, controls and r2 of standard curve were calculated
using the Gen5 software. The Gen5 program 4-
parameter logistic standard curve is delineated by the
formula; Y = (A-D)/(1+ (X/C)B) + D where ‘Y’ is the op-
tical density (OD) of the test/control sample, ‘A’ is the re-
sponse at zero concentration, ‘B’ is the measure of the
slope curve at its inflection point, ‘C’ is the value of X at
inflection point and ‘D’ is the response at infinite con-
centration. This equation defines the relationship be-
tween obtained absorbance values and the known
concentrations of a reference standard [30,47].
In evaluating the assay standard curve, we expressed
the predicted standard concentrations as a percentage
recovery (%Re) at each concentration level, %Re = 100
(BC/NC), where BC and NC represent the back-
calculated and nominal (known) concentrations respect-
ively. Curve fitting was done using SigmaPlot (Systat
software Inc, San Jose, USA) and data were analysed
with the statistical software package SPSS Version 21
(IBM SPSS Statistics; IBM Corporation, Armonk, New
York, USA). Correlations at the p ≤ 0.01 level was con-
sidered statistically significant.
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